These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31959504)

  • 1. WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019.
    Wadhwa M; Kang HN; Jivapaisarnpong T; ; Andalucia LR; Blades CDRZ; Casas Levano M; Chang W; Chew JY; Chilufya MB; Chirachanakul P; Cho HG; Cho YO; Choi KM; Chong S; Chua HM; Farahani AV; Gencoglu M; Ghobrial MRW; Guha P; Gutierrez Lugo MT; Ha SB; Habahbeh S; Hamel H; Hong Y; Iarutkin A; Jang H; Jayachandran R; Jivapaisarnpong T; Kang HN; Kim DY; Kim GH; Kim Y; Kwon HS; Larsen J; Lee AH; Lee J; Medvedeva K; Munkombwe Z; Oh I; Park J; Park J; Putri DE; Rodgers J; Ryu S; Savkina M; Schreitmueller T; Semeniuk O; Seo M; Shin YI; Shin J; Srivastava S; Song H; Song S; Tavares Neto J; Wadhwa M; Yamaguchi T; Youn HD; Yun M
    Biologicals; 2020 May; 65():50-59. PubMed ID: 31959504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality changes to approved biotherapeutic product: Simulated case studies on reporting categories & supporting data requirements.
    Hamel H; Kang HN
    Biologicals; 2019 Nov; 62():1-7. PubMed ID: 31668453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017.
    Wadhwa M; Kang HN; Hamel H; Jivapaisarnpong T;
    Biologicals; 2018 Mar; 52():83-91. PubMed ID: 29289489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010.
    Wadhwa M; Kang HN; Knezevic I; Thorpe R; Griffiths E
    Biologicals; 2011 Sep; 39(5):349-57. PubMed ID: 21906959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products.
    Schiestl M
    Biologicals; 2011 Sep; 39(5):297-9. PubMed ID: 21784654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019.
    Kang HN; Thorpe R; Knezevic I;
    Biologicals; 2020 May; 65():1-9. PubMed ID: 32224101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June - 2 July 2021.
    Wadhwa M; Kang HN; Thorpe R; Knezevic I; ; Aprea P; Bielsky MC; Ekman N; Heim HK; Joung J; Kurki P; Lacana E; Njue C; Nkansah E; Savkina M; Thorpe R; Yamaguchi T; Wadhwa M; Wang J; Weise M; Wolff-Holz E; ; ; ; ; ; ; ;
    Biologicals; 2022 Apr; 76():1-9. PubMed ID: 35466023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches.
    Fletcher MP
    Biologicals; 2011 Sep; 39(5):270-7. PubMed ID: 21875812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation workshop of WHO guidelines on evaluation of malaria vaccines: Current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014.
    Ho MM; Baca-Estrada M; Conrad C; Karikari-Boateng E; Kang HN
    Vaccine; 2015 Aug; 33(36):4359-64. PubMed ID: 26165916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO/KFDA workshop on stability evaluation of vaccines, Seoul, Korea, 23-25 April 2008.
    Shin J; Smith D; Southern J; Knezevic I
    Biologicals; 2009 Nov; 37(6):435-44; discussion 421-3. PubMed ID: 19783459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010).
    Kang HN
    Biologicals; 2011 Sep; 39(5):304-7. PubMed ID: 21880507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products.
    Knezevic I; Griffiths E
    Ann N Y Acad Sci; 2017 Nov; 1407(1):5-16. PubMed ID: 28905423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
    Knezevic I
    Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical programs in the development of similar biotherapeutic products: rationale and general principles.
    Berghout A
    Biologicals; 2011 Sep; 39(5):293-6. PubMed ID: 21911300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility.
    Wadhwa M; Knezevic I; Kang HN; Thorpe R
    Biologicals; 2015 Sep; 43(5):298-306. PubMed ID: 26144595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability.
    Vinther A; Ramnarine E; Gastineau T; O'Brien L; Brehm O; Fryrear D
    Ther Innov Regul Sci; 2024 May; 58(3):433-442. PubMed ID: 38369639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards regulation of similar biotherapeutic products: Thailand's perspective.
    Thanaphollert P; Tungsanga K
    Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
    Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
    Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unleashing the Power of Reliance for Post-Approval Changes: A Journey with 48 National Regulatory Authorities.
    Mangia F; Lin YM; Armando J; Dominguez K; Rozhnova V; Ausborn S
    Ther Innov Regul Sci; 2024 Nov; 58(6):997-1005. PubMed ID: 39048766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.